Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

被引：0
|
作者：
Usmani, Saad [1 ]
Sexton, Rachael [2 ]
Hoering, Antje [2 ]
Heuck, Christoph [1 ]
Nair, Bijay [1 ]
Waheed, Sarah [1 ]
Alsayed, Yazan [1 ]
Petty, Nathan M. [1 ]
Crowley, John [2 ]
Barlogie, Bart [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Canc Res & Biostat, Res & Biostat, Seattle, WA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [41] Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-analysis Of Randomized Trials
    Singh, Preet Paul
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Gertz, Morie A.
    Dispenzieri, Angela
    Bergsagel, P. Leif
    Lacy, Martha Q.
    Singh, Siddharth
    Roy, Vivek
    Buadi, Francis K.
    Dingli, David
    Kyle, Robert
    Rajkumar, S. Vincent
    Kapoor, Prashant
    BLOOD, 2013, 122 (21)
  • [42] Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Srivastava, G.
    Rana, V.
    Lacy, M. Q.
    Buadi, F. K.
    Hayman, S. R.
    Dispenzieri, A.
    Gertz, M. A.
    Dingli, D.
    Zeldenrust, S.
    Russell, S.
    McCurdy, A.
    Kapoor, P.
    Kyle, R.
    Rajkumar, S. V.
    Kumar, S.
    LEUKEMIA, 2013, 27 (10) : 2062 - 2066
  • [43] Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    G Srivastava
    V Rana
    M Q Lacy
    F K Buadi
    S R Hayman
    A Dispenzieri
    M A Gertz
    D Dingli
    S Zeldenrust
    S Russell
    A McCurdy
    P Kapoor
    R Kyle
    S V Rajkumar
    S Kumar
    Leukemia, 2013, 27 : 2062 - 2066
  • [44] The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
    Maximilian Merz
    Tobias Dechow
    Mithun Scheytt
    Christian Schmidt
    Bjoern Hackanson
    Stefan Knop
    Annals of Hematology, 2020, 99 : 1709 - 1725
  • [45] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Joseph, Nisha
    Almaula, Dhwani
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay
    BLOOD, 2017, 130
  • [46] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
    Slade, Michael
    Martin, Thomas G.
    Nathwani, Nitya
    Fiala, Mark A.
    Rettig, Michael P.
    Gao, Feng
    Deol, Abhinav
    Buadi, Francis K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Gregory, Tara K.
    Berdeja, Jesus
    Chari, Ajai
    Rosko, Ashley
    Vij, Ravi
    LEUKEMIA, 2022, 36 (12) : 2917 - 2921
  • [47] Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Huston, Alissa
    Brown, Jason
    Roodman, G. David
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (12) : 1616 - 1616
  • [48] Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy
    Askman, Sandra
    Westerlund, Julia
    Pettersson, Asa
    Hellmark, Thomas
    Johansson, Asa
    Wichert, Stina
    Hansson, Markus
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (01) : 72 - 81
  • [49] The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
    Merz, Maximilian
    Dechow, Tobias
    Scheytt, Mithun
    Schmidt, Christian
    Hackanson, Bjoern
    Knop, Stefan
    ANNALS OF HEMATOLOGY, 2020, 99 (08) : 1709 - 1725
  • [50] CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Vasquez, J.
    Ruiz, R.
    Aliaga, K.
    Valencia, F.
    Enriquez, D.
    Palacios, V.
    Quintana, S.
    Casanova, L.
    HAEMATOLOGICA, 2016, 101 : 798 - 798
12345